سعر ماريفان 5 مجم 100 قرص 2026

Marevan 5 mg oral tablets (warfarin), pack of 100 tablets, by GlaxoSmithKline (Egypt); an oral vitamin K antagonist anticoagulant.

• Prophylaxis and treatment of venous thrombosis and its extension, and pulmonary embolism.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Reduction in the risk of death, recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common: fatal and non-fatal haemorrhage from any tissue or organ. Others: hypersensitivity (urticaria, anaphylaxis), vasculitis, hepatitis/elevated liver enzymes, nausea, vomiting, diarrhoea, taste perversion, abdominal pain, flatulence, bloating, rash, dermatitis, pruritus, alopecia, tracheal calcification, chills.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy, except in pregnant women with mechanical heart valves at high risk of thromboembolism.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Haemorrhagic tendencies or blood dyscrasias; recent or contemplated CNS or eye surgery or traumatic surgery with large open surfaces; bleeding tendencies (active ulceration or overt bleeding of GI, genitourinary or respiratory tract, CNS haemorrhage, cerebral aneurysm, dissecting aorta, pericarditis/pericardial effusion, bacterial endocarditis); threatened abortion, eclampsia, pre-eclampsia; unsupervised patients with potential high non-compliance; spinal puncture or procedures with potential for uncontrollable bleeding; major regional or lumbar block anaesthesia; malignant hypertension; hypersensitivity to warfarin or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: warfarin can cause major or fatal bleeding; perform regular INR monitoring in all patients; drugs, dietary changes and other factors affect INR.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other serious risks: tissue necrosis, calciphylaxis, acute kidney injury, systemic atheroemboli and cholesterol microemboli, and limb ischaemia/necrosis when started in heparin-induced thrombocytopenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs that increase bleeding risk (anticoagulants, antiplatelet agents incl. aspirin and clopidogrel, NSAIDs, SSRIs/SNRIs)Concomitant use increases bleeding risk; monitor closely.DailyMed (U.S. National Library of Medicine)
• CYP2C9, CYP1A2 and CYP3A4 inhibitors (e.g. amiodarone, fluconazole, metronidazole, cotrimoxazole) and inducers (e.g. carbamazepine, phenobarbital, rifampin)Inhibitors may increase and inducers may decrease INR; closely monitor INR when starting, stopping or changing them.DailyMed (U.S. National Library of Medicine)
• Antibiotics and antifungalsChanges in INR have been reported; closely monitor INR when starting or stopping any antibiotic or antifungal.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy except in women with mechanical heart valves at high risk of thromboembolism, where benefits may outweigh risks; warfarin can cause fetal harm.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Warfarin was not detected in human milk in a limited study (15 mothers); weigh benefits of breastfeeding against risks and monitor breastfed infants for bruising or bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Warfarin: Inhibits vitamin K epoxide reductase (VKORC1), reducing regeneration of reduced vitamin K and hence synthesis of active vitamin K-dependent clotting factors II, VII, IX and X and proteins C and S.